About 81,000 people in that age category who have received one shot of Moderna would be offered a different coronavirus vaccine for their second dose.Īnders Tegnell, Sweden’s chief epidemiologist, said health officials would “follow the situation closely and act quickly to ensure that vaccinations against Covid-19 are always as safe as possible and at the same time provide effective protection” against the disease.ĭenmark's decision to halt the use of the Moderna Covid-19 vaccine for under-18s comes after it completely stopped using the AstraZeneca vaccine. The agency said it was now recommending the Pfizer vaccine for Swedes born in 1991 or later. But the agency stressed that the risk of developing such side effects was "very small". The EMA approved the use of Comirnaty in May, while Spikevax was given the nod for children over 12 in July.The connection, it said, was especially clear when it came to Moderna's vaccine Spikevax, especially after the second dose. “Men under the age of 30 should also consider choosing Cominarty when they get vaccinated,” Geir Bukholm, head of infection control at the Norwegian Institute of Public Health, said in a statement.Ī Finnish health official said Finland expected to publish a decision on Thursday. Norway already recommends the Cominarty vaccine to minors and said on Wednesday that it was reiterating this. The vaccine is not approved for people under age 18 in the United States. vaccine safety monitoring databases has also suggested that Moderna’s vaccine may carry a higher risk of myocarditis among young people. The benefits of shots based on so-called mRNA technology used by both Moderna and Pfizer-BioNTech in preventing COVID-19 continue to outweigh the risks, regulators in the United States, EU and the World Health Organization have said.ĭata suggests reported cases of rare heart inflammation are relatively higher after Moderna’s vaccine compared with the Pfizer/BioNTech shots, Canadian health officials said last week.Īlthough both vaccines are based on mRNA technology, the Pfizer shot contains 30 micrograms of vaccine per dose compared with 100 micrograms in the Moderna vaccine.ĭata from one of two U.S. The EMA’s safety committee concluded in July that inflammatory heart conditions can occur in very rare cases following vaccination with Comirnaty or Spikevax, more often in younger men after the second dose. ![]() The Danish Health Authority said it had made the decision even as “heart inflammation is an extremely rare side effect that often has a mild course and goes away on its own”. Sweden and Denmark said they now recommended the Comirnaty vaccine, from Pfizer/BioNTech, instead. Final data was expected within a month, it added. It referred to data from a yet unpublished Nordic study, which would now be sent to the European Medicines Agency (EMA) for further assessment. “In the preliminary data … there is a suspicion of an increased risk of heart inflammation, when vaccinated with Moderna,” the Danish Health Authority said in a statement. study that has yet to undergo peer review young males under 20 are up to six times more likely to develop myocarditis after contracting COVID-19 than those who have been vaccinated.ĭenmark said that, while it used the Pfizer/BioNTech vaccine as its main option for people aged 12-17 years, it had decided to pause giving the Moderna vaccine to people below 18 according to a “precautionary principle”. “These are typically mild cases and individuals tend to recover within a short time following standard treatment and rest. The risk of myocarditis is substantially increased for those who contract COVID-19, and vaccination is the best way to protect against this.”Īccording to one U.S. ![]() Shares of Moderna fell 4.9%, or $16.08, to $316.11 in afternoon trading.Ī Moderna spokesperson said in an email the company was aware of the decisions by regulators in Denmark and Sweden to pause the use of its vaccine in younger individuals because of the rare risk of myocarditis and or pericarditis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |